Garr's panel, from 2:30 3:30, will discuss "TreatmentWhat's Working and What is Under Development." He will focus on NSI-189, Neuralstem's lead neurogenic compound, which is currently in a Phase Ib clinical trial in major depressive disorder .
http://www.biospace.com/news_story.aspx?StoryID=293734&full=1
http://www.biospace.com/news_story.aspx?StoryID=293734&full=1
No comments:
Post a Comment